Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Current Liabilities (2019 - 2025)

Eton Pharmaceuticals' Total Current Liabilities history spans 7 years, with the latest figure at $44.2 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 123.89% year-over-year to $44.2 million; the TTM value through Sep 2025 reached $44.2 million, up 123.89%, while the annual FY2024 figure was $19.9 million, 22.82% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $44.2 million at Eton Pharmaceuticals, up from $38.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $44.2 million in Q3 2025 and bottomed at $3.1 million in Q2 2021.
  • The 5-year median for Total Current Liabilities is $9.6 million (2023), against an average of $13.7 million.
  • The largest annual shift saw Total Current Liabilities decreased 13.04% in 2022 before it skyrocketed 151.52% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $4.6 million in 2021, then skyrocketed by 41.75% to $6.5 million in 2022, then surged by 151.37% to $16.2 million in 2023, then rose by 22.82% to $19.9 million in 2024, then surged by 121.5% to $44.2 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Total Current Liabilities are $44.2 million (Q3 2025), $38.6 million (Q2 2025), and $25.3 million (Q1 2025).